While increasing glucokinase activity (e.g. through GKRP inhibition or allosteric activation) could lower plasma glucose to reduce the risk of type 2 diabetes, genetic evidence also points to the possibility of likely adverse effects [40–42]. This evidence concerns the gene GCKR and type 2 diabetes mellitus.